Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5900930 | 0.92 | SMO (0.54) | ALDH1A1TSHRMEN1TTRADORA3 | |
| SCHEMBL7828458 | 0.87 | HSD17B10 (0.50) | ALDH1A1MEN1KMT2ACYP1A2HPGD | |
| SCHEMBL1272335 | 0.85 | PDK1 (0.53) | ALDH1A1MEN1KMT2ACYP1A2LMNA | |
| SCHEMBL7308406 | 0.83 | TSHR (0.59) | ALDH1A1TSHRMEN1TTRADORA3 | |
| SCHEMBL8118111 | 0.83 | NR4A2 (0.48) | ALDH1A1TSHRMEN1PTGS2KMT2A | |
| Hydrochloric Acid SCHEMBL5297660 | 0.83 | PDK1 (0.51) | ALDH1A1MEN1KMT2ACYP1A2LMNA | |
| SCHEMBL5176800 | 0.81 | TSHR (0.49) | ALDH1A1TSHRMEN1TTRADORA3 | |
| SCHEMBL10496983 | 0.80 | POLB (0.40) | ALDH1A1KMT2ACYP1A2HPGDCYP2C19 | |
| SCHEMBL25258585 | 0.80 | PTPN11 (0.55) | ALDH1A1CYP1A2HPGDCYP2C19LMNA | |
| SCHEMBL950942 | 0.80 | POLB (0.62) | ALDH1A1MEN1PTGS2AKR1C3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2388003-B1 | Colchicine derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3207929-B1 | COLCHICINE DERIVATIVES FOR THE TREATMENT OF CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3207929-A2 | COLCHICINE DERIVATIVES | California Pacific Medical Center (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-1617843-B1 | COLCHICINE DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-1643987-B1 | PODOPHYLLOTOXIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2016-11-30 | — | — | EP | disclosed |
| CN-102643241-A | Compounds and compositions and methods of use | ARDEA BIOSCIENCES INC | 2012-08-22 | — | — | CN | disclosed |
| US-8158809-B2 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2388003-A2 | Colchicine derivatives | California Pacific Medical Center (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | Sutter West Bay Hospitals, dba California Pacific Medical Center and Catholic Healthcare West | 2009-12-03 | — | — | US | disclosed |
| US-7605262-B2 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS (US) | 2009-10-20 | — | — | US | disclosed |
| US-7342114-B2 | Podophyllotoxin derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1643987-A2 | PODOPHYLLOTOXIN DERIVATIVES | California Pacific Medical Center (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1617843-A2 | COLCHICINE DERIVATIVES | California Pacific Medical Center (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2005014536-A2 | PODOPHYLLOTOXIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005007076-A2 | COLCHICINE DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050004169-A1 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2005-01-06 | — | — | US | disclosed |
| US-6825236-B2 | ACTIVE AGAINST TUMORS IN MICE AND ARE GENERALLY WELL TOLERATED | CALIFORNIA PACIFIC MEDICAL CENTER | 2004-11-30 | — | — | US | disclosed |
| US-20040204370-A1 | COLCHICINE DERIVATIVES | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2004-10-14 | — | — | US | disclosed |
| US-6576614-B1 | Administering methyl ketones or closed hemiketal derivatives of aspartic acid | VERTEX PHARMACEUTICALS INCORPORATED | 2003-06-10 | — | — | US | disclosed |
| US-4307113-A | TREATMENT OF DIABETES | SANDOZ, INC. (US) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004169-A1 | Podophyllotoxin derivatives | APEH, DAGLA, DPY30 | ALDH1A1 285/4885TSHR 3451/4885MEN1 4599/4885 |
| US-20040204370-A1 | COLCHICINE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, NAP1L4 | ALDH1A1 2730/4885TSHR 3779/4885MEN1 1453/4885 |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | APEH, DAGLA, DPY30 | ALDH1A1 285/4885TSHR 3451/4885MEN1 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.